Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC versus CYKLX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC versus CYKLX.
AMINOCAPROIC vs CYKLX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation and, to a lesser extent, noncompetitive inhibition of plasmin, thereby preventing fibrinolysis and promoting clot stability.
CYKLX is a selective phosphodiesterase 4 (PDE4) inhibitor, increasing intracellular cyclic adenosine monophosphate (cAMP) levels and reducing pro-inflammatory cytokine production.
4-5 g orally or intravenously as a loading dose, followed by 1 g/hour continuous infusion or 1 g every 4-6 hours orally. Maximum dose 30 g/day.
100 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged to 4–10 hours in renal impairment. Clinically, dosing interval must be adjusted in renal dysfunction to avoid accumulation.
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal half-life: 12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (>95%) as unchanged drug via glomerular filtration and tubular secretion. Less than 1% biliary/fecal.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Category C
Category C
Antifibrinolytic
Antifibrinolytic